<DOC>
	<DOCNO>NCT01475721</DOCNO>
	<brief_summary>The purpose study ass whether risk serious asthma-related event ( asthma-related hospitalization , endotracheal intubation , death ) adolescent adult ( 12 year age old ) take inhaled fluticasone propionate/salmeterol combination take inhaled fluticasone propionate alone . ADVAIR™ FLOVENT™ trademark GlaxoSmithKline Group Companies .</brief_summary>
	<brief_title>SAS115359 : A 6-month Study Assess Safety Benefit Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate Treatment Adolescents Adults ( 12 Years Age Older ) With Asthma .</brief_title>
	<detailed_description>Progress Enrollment , Updated Annually : This study complete final clinical study report submit FDA January 2016 . This final update , study complete .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Provided consent participate study Male female , 12 year age old Clinical diagnosis asthma least 1 year prior randomization Clinic PEF great equal 50 % predict normal value Subject must appropriately use one treatment asthma list protocol Subject must able complete asthma control questionnaire , daily question asthma , use DISKUS inhaler Subject must history least 1 asthma exacerbation include one follow year prior randomization : requiring treatment systemic corticosteroid asthmarelated hospitalization History life threaten asthma define protocol asthma episode require intubation and/or associate hypercapnea require noninvasive ventilatory support Concurrent respiratory disease asthma Current evidence , ever tell physician chronic bronchitis , emphysema , chronic obstructive pulmonary disease . Exercise induced asthma ( asthmarelated diagnosis ) require daily asthma control medicine Presence bacterial viral respiratory infection resolve randomization An asthma exacerbation require systemic corticosteriods within 4 week randomization 4 separate exacerbation 12 month precede randomization More 2 hospitalization treatment asthma 12 month precede randomization Subject must meet unstable asthma severity criterion list protocol Potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor within last 4 week ( e.g. , ritonavir , ketoconazole , itraconzole ) Pregnancy , breastfeed plan pregnancy study A Child Care ( CiC ) child place control protection agency , organisation , institution entity court , government government body , act accordance power confer law regulation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ADVAIR</keyword>
	<keyword>Asthma</keyword>
	<keyword>safety</keyword>
	<keyword>FLOVENT</keyword>
</DOC>